Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Abstract Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were rando...
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Nature Portfolio
2023-04-01
|
| Цуврал: | Nature Communications |
| Онлайн хандалт: | https://doi.org/10.1038/s41467-023-37648-w |